Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 43,502 Shares

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 43,502 shares of Natera stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $176.88, for a total transaction of $7,694,633.76. Following the transaction, the chief financial officer now directly owns 70,629 shares of the company’s stock, valued at approximately $12,492,857.52. This trade represents a 38.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The shares were sold at an average price of $165.87, for a total transaction of $719,046.45.
• On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The stock was sold at an average price of $176.60, for a total value of $333,067.60.
• On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The shares were sold at an average price of $161.87, for a total value of $233,416.54.
• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The stock was sold at an average price of $171.98, for a total value of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $4,277,837.07.

Natera Stock Performance

Shares of Natera stock traded down $2.32 on Tuesday, hitting $174.24. 1,124,858 shares of the company’s stock were exchanged, compared to its average volume of 1,398,383. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The stock has a market capitalization of $23.00 billion, a PE ratio of -99.00 and a beta of 1.66. Natera, Inc. has a 1 year low of $66.68 and a 1 year high of $183.00. The company has a 50-day simple moving average of $167.26 and a 200-day simple moving average of $139.52.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. The business had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera’s revenue for the quarter was up 63.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.95) earnings per share. As a group, equities analysts anticipate that Natera, Inc. will post -1.56 EPS for the current year.

Analyst Ratings Changes

NTRA has been the subject of several recent analyst reports. TD Cowen lifted their target price on shares of Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Barclays started coverage on Natera in a research report on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 price objective on the stock. Piper Sandler lifted their target price on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, November 18th. Sanford C. Bernstein boosted their price target on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, January 10th. Finally, JPMorgan Chase & Co. increased their price objective on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $165.88.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Chartwell Investment Partners LLC lifted its holdings in Natera by 37.9% during the third quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock valued at $5,243,000 after purchasing an additional 11,362 shares in the last quarter. Cerity Partners LLC raised its position in shares of Natera by 27.0% during the 3rd quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock valued at $10,936,000 after purchasing an additional 18,316 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Natera during the 3rd quarter valued at $385,000. Everence Capital Management Inc. bought a new position in Natera in the 4th quarter worth $573,000. Finally, First Turn Management LLC purchased a new stake in Natera in the 3rd quarter worth $19,760,000. 99.90% of the stock is currently owned by institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.